Literature DB >> 12377930

Potential role of the formyl peptide receptor-like 1 (FPRL1) in inflammatory aspects of Alzheimer's disease.

Youhong Cui1, Yingying Le, Hiroshi Yazawa, Wanghua Gong, Ji Ming Wang.   

Abstract

Alzheimer's disease (AD) is a progressive, neurodegenerative disease characterized by the presence of multiple senile plaques in the brain tissue, which are also associated with considerable inflammatory infiltrates. Although the precise mechanisms of the pathogenesis of AD remain to be determined, the overproduction and precipitation of a 42 amino acid form of beta amyloid (Abeta(42)) in plaques have implicated Abeta in neurodegeneration and proinflammatory responses seen in the AD brain. Our recent studies revealed that the activation of formyl peptide receptor-like 1 (FPRL1), a seven-transmembrane, G-protein-coupled receptor, by Abeta(42) may be responsible for accumulation and activation of mononuclear phagocytes (monocytes and microglia). We further found that upon binding FPRL1, Abeta(42) was rapidly internalized into the cytoplasmic compartment in the form of Abeta(42)/FPRL1 complexes. Persistent exposure of FPRL1-expressing cells to Abeta(42) resulted in intracellular retention of Abeta(42)/FPRL1 complexes and the formation of Congo-red-positive fibrils in mononuclear phagocytes. Our observations suggest that FPRL1 may not only mediate the proinflammatory activity of Abeta(42) but also actively participate in Abeta(42) uptake and the resultant fibrillar formation. Therefore, FPRL1 may constitute an additional molecular target for the development of therapeutic agents for AD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12377930

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  31 in total

Review 1.  Microglia and inflammation in Alzheimer's disease.

Authors:  Shweta Mandrekar-Colucci; Gary E Landreth
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-04       Impact factor: 4.388

2.  FPRL-1 Receptor Modulators May Provide Treatment for Inflammation.

Authors:  Ahmed F Abdel-Magid
Journal:  ACS Med Chem Lett       Date:  2013-05-16       Impact factor: 4.345

Review 3.  Microglial Aβ receptors in Alzheimer's disease.

Authors:  Yang Yu; Richard D Ye
Journal:  Cell Mol Neurobiol       Date:  2014-08-23       Impact factor: 5.046

Review 4.  Development of small molecule non-peptide formyl peptide receptor (FPR) ligands and molecular modeling of their recognition.

Authors:  I A Schepetkin; A I Khlebnikov; M P Giovannoni; L N Kirpotina; A Cilibrizzi; M T Quinn
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

5.  Adaptive evolution of formyl peptide receptors in mammals.

Authors:  Yoshinori Muto; Stéphane Guindon; Toshiaki Umemura; László Kőhidai; Hiroshi Ueda
Journal:  J Mol Evol       Date:  2015-01-28       Impact factor: 2.395

6.  Functional N-Formyl Peptide Receptor 2 (FPR2) Antagonists Based on the Ureidopropanamide Scaffold Have Potential To Protect Against Inflammation-Associated Oxidative Stress.

Authors:  Madia L Stama; Enza Lacivita; Liliya N Kirpotina; Mauro Niso; Roberto Perrone; Igor A Schepetkin; Mark T Quinn; Marcello Leopoldo
Journal:  ChemMedChem       Date:  2017-11-07       Impact factor: 3.466

7.  Synthesis, enantioresolution, and activity profile of chiral 6-methyl-2,4-disubstituted pyridazin-3(2H)-ones as potent N-formyl peptide receptor agonists.

Authors:  Agostino Cilibrizzi; Igor A Schepetkin; Gianluca Bartolucci; Letizia Crocetti; Vittorio Dal Piaz; Maria Paola Giovannoni; Alessia Graziano; Liliya N Kirpotina; Mark T Quinn; Claudia Vergelli
Journal:  Bioorg Med Chem       Date:  2012-04-27       Impact factor: 3.641

Review 8.  International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family.

Authors:  Richard D Ye; François Boulay; Ji Ming Wang; Claes Dahlgren; Craig Gerard; Marc Parmentier; Charles N Serhan; Philip M Murphy
Journal:  Pharmacol Rev       Date:  2009-06-04       Impact factor: 25.468

9.  Further studies on 2-arylacetamide pyridazin-3(2H)-ones: design, synthesis and evaluation of 4,6-disubstituted analogs as formyl peptide receptors (FPRs) agonists.

Authors:  Maria Paola Giovannoni; Igor A Schepetkin; Agostino Cilibrizzi; Letizia Crocetti; Andrei I Khlebnikov; Claes Dahlgren; Alessia Graziano; Vittorio Dal Piaz; Liliya N Kirpotina; Serena Zerbinati; Claudia Vergelli; Mark T Quinn
Journal:  Eur J Med Chem       Date:  2013-04-08       Impact factor: 6.514

10.  Pathogenic Bacterial Proteins and their Anti-Inflammatory Effects in the Eukaryotic Host.

Authors:  Jun Sun
Journal:  Antiinflamm Antiallergy Agents Med Chem       Date:  2009-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.